Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy without Choroidal Neovascular Membrane - a Pilot Study
PURPOSE: To study intravitreal brolucizumab in the management of persistent macular fluid in chronic central serous chorioretinopathy (CSCR) without choroidal neovascular membrane (CNVM).
METHODS: Retrospective case series which included eyes with chronic CSCR with persistent macular fluid for ≥ 3 months without CNVM. Intravitreal brolucizumab was administered in all eyes. Primary outcome measure was the resolution of intraretinal (IRF) and/or subretinal fluid (SRF) on OCT.
RESULTS: Five eyes (four patients) with chronic CSCR were included. All eyes showed complete resolution of SRF 1 month following injection. Minimal residual IRF was present in two eyes. Best corrected visual acuity (BCVA) was stable in three eyes, and two eyes showed improvement. Central macular thickness (CMT) and subfoveal choroidal thickness (SFCT) showed reduction.
CONCLUSION: Intravitreal brolucizumab is effective in the rapid reduction of persistent macular fluid in chronic CSCR without CNVM. Long-term follow-up data are required to study recurrence and adverse effect profile.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Seminars in ophthalmology - (2024) vom: 25. Jan., Seite 1-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ramamurthy, Srishti Raksheeth [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Brolucizumab |
|---|
| Anmerkungen: |
Date Revised 25.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/08820538.2024.2308808 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367605481 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367605481 | ||
| 003 | DE-627 | ||
| 005 | 20240125232256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/08820538.2024.2308808 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1270.xml |
| 035 | |a (DE-627)NLM367605481 | ||
| 035 | |a (NLM)38270124 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ramamurthy, Srishti Raksheeth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy without Choroidal Neovascular Membrane - a Pilot Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a PURPOSE: To study intravitreal brolucizumab in the management of persistent macular fluid in chronic central serous chorioretinopathy (CSCR) without choroidal neovascular membrane (CNVM) | ||
| 520 | |a METHODS: Retrospective case series which included eyes with chronic CSCR with persistent macular fluid for ≥ 3 months without CNVM. Intravitreal brolucizumab was administered in all eyes. Primary outcome measure was the resolution of intraretinal (IRF) and/or subretinal fluid (SRF) on OCT | ||
| 520 | |a RESULTS: Five eyes (four patients) with chronic CSCR were included. All eyes showed complete resolution of SRF 1 month following injection. Minimal residual IRF was present in two eyes. Best corrected visual acuity (BCVA) was stable in three eyes, and two eyes showed improvement. Central macular thickness (CMT) and subfoveal choroidal thickness (SFCT) showed reduction | ||
| 520 | |a CONCLUSION: Intravitreal brolucizumab is effective in the rapid reduction of persistent macular fluid in chronic CSCR without CNVM. Long-term follow-up data are required to study recurrence and adverse effect profile | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Brolucizumab | |
| 650 | 4 | |a CSCR | |
| 650 | 4 | |a chronic | |
| 650 | 4 | |a complex CSCR | |
| 650 | 4 | |a persistent fluid | |
| 700 | 1 | |a Behera, Umesh Chandra |e verfasserin |4 aut | |
| 700 | 1 | |a Narula, Ritesh |e verfasserin |4 aut | |
| 700 | 1 | |a Sadda, SriniVas R |e verfasserin |4 aut | |
| 700 | 1 | |a Narayanan, Raja |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in ophthalmology |d 1990 |g (2024) vom: 25. Jan., Seite 1-8 |w (DE-627)NLM08584845X |x 1744-5205 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:25 |g month:01 |g pages:1-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/08820538.2024.2308808 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 25 |c 01 |h 1-8 | ||